ERBB2 and breast carcinoma: For example, in human epidermal growth factor receptor 2 (HER2)‐positive breast cancer, the APHINITY trial demonstrated that adding pertuzumab to standard adjuvant, combination chemotherapy improved 3‐year invasive disease‐free survival from 93% to 94%.